- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01552603
Artificial Pancreas Control System in an Inpatient Setting
April 27, 2016 updated by: W. Kenneth Ward, Legacy Health System
Sensor-controlled Insulin- and Glucagon Delivery in Subjects With Type 1 Diabetes: Testing of an Automated System in a Supervised Inpatient Setting
The purpose of this study is to verify an automated system of blood glucose control in Type I Diabetics.
The automated system consists of the investigational Artificial Pancreas Control software (APC), two blood glucose sensors, and two hormone pumps, one for delivering insulin to lower blood sugar, and the second for delivering glucagon to raise blood sugar.
The blood glucose sensors relays information to the Artificial Pancreas software, which uses the Adaptive Proportional Device algorithm to determine the rate of insulin and glucagon infusion by the hormone pumps.
In prior studies, the Adaptive Proportional Device algorithm has been verified, but required manual input into the computer and hormone pumps.
This study differs in that it uses a fully automated system under the control of the Artificial Pancreas Control software.
The importance of this change is that it is the next step to enable outpatient use of automated, closed loop blood glucose control.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objective of the current human study is to verify the components of the Artificial Pancreas Control system during an inpatient study.
This master controller software is designed to be used in conjunction with two subcutaneous continuous glucose monitoring systems to regulate blood glucose levels as well as two Omnipod pumps, one for administering insulin and one for administering glucagon.
The sensors communicate wirelessly with two sensor receivers which will be interfaced with the APC by wireless USB connection.
The insulin and glucagon pumps will be controlled by the APC through a wireless USB connection.
The algorithm included in the APC is an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm, which was previously studied as an investigational device.
The APD has been studied in vivo (in 28 experiments, each 33 hr in length, with manual adjustment of pumps) and no serious adverse effects were noted.
Manual input of the glucose sensor data and insulin/glucagon infusion rates will no longer be necessary.
The APC will be tested in vivo during 28 hour experiments in an inpatient setting in preparation for outpatient testing.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
Portland, Oregon, United States, 97210
- Legacy Good Samaritan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of type 1 diabetes mellitus for at least 1 year.
- Male or female subjects 21 to 65 years of age.
- Current use of an insulin pump.
- Willingness to follow all study procedures, including attending all clinic visits.
- Willingness to sign informed consent and HIPAA documents.
Exclusion Criteria:
- Pregnancy or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
- Renal insufficiency (serum creatinine of 2.0 mg/dL or greater).
- Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.3 g/dL; or serum bilirubin of over 2.
- Adrenal insufficiency
- Hematocrit of less than or equal to 34%.
- A history of cerebrovascular disease or coronary artery disease regardless of the time since occurrence.
- Congestive heart failure, NYHA class III or IV.
- Diagnosis of 2nd or 3rd degree heart block or any arrhythmia judged by the investigator to be exclusionary.
- Any active infection.
- Visual impairment preventing reading of glucose meter values or continuous glucose monitoring device.
- Physical impairment impeding the ability to use a glucose meter or glucose monitoring device.
- Active foot ulceration.
- Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication.
- Active alcohol abuse, substance abuse, or severe mental illness (as judged by the principal investigator).
- Active malignancy, except basal cell or squamous cell skin cancers.
- Major surgical operation within 30 days prior to screening.
- Seizure disorder.
- Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
- Current administration of oral or parenteral corticosteroids.
- Use of an investigational drug within 30 days prior to screening.
- Bleeding disorder, treatment with warfarin, or platelet count below 50,000.
- Allergy to aspart insulin.
- Allergy to glucagon.
- Past history of pheochromocytoma or a family history of MEN 2, neurofibromatosis, or von Hippel-Lindau disease.
- Insulin resistance requiring more than 200 units per day.
- Need for uninterrupted treatment of acetaminophen.
- Intolerance of mild hypoglycemia (glucose 60-70 mg/dl).
- History of hypoglycemic unawareness.
- Insulin antibody level of ≥ 100 µUnits/ml.
- C peptide level of ≥0.5 ng/ml.
- Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen.
- Any reason the principal investigator deems exclusionary
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Artificial Pancreas Control
Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours.
For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
|
This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels.
The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent of Time in Target Blood Glucose Range
Time Frame: all 28 hour studies
|
Mean percent of time venous blood glucose was sampled between 70-180 mg/dl
|
all 28 hour studies
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Deviation From Target Blood Glucose
Time Frame: all 28 hour studies
|
Mean difference of venous blood glucose from glucose target.
Daytime venous blood glucose values (7am-11pm) subtracted from daytime target of 115 mg/dl.
Nighttime venous blood glucose values (11pm-7am) subtracted from nighttime target of 140 mg/dl.
This is a metric of how successful the closed loop algorithm was at controlling glucose.
|
all 28 hour studies
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (ACTUAL)
August 1, 2013
Study Completion (ACTUAL)
September 1, 2013
Study Registration Dates
First Submitted
February 22, 2012
First Submitted That Met QC Criteria
March 9, 2012
First Posted (ESTIMATE)
March 13, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
June 3, 2016
Last Update Submitted That Met QC Criteria
April 27, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011.11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type I Diabetes Mellitus
-
Hadassah Medical OrganizationOramed Pharmaceutical Inc.CompletedBrittle Type I Diabetes MellitusIsrael
-
Nemours Children's ClinicThrasher Research FundCompleted
-
Medtronic Diabetes R&D DenmarkUnknownDiabetes Mellitus Type II | Diabetes Mellitus Type IDenmark
-
Northwestern UniversityUniversity of Illinois at ChicagoCompletedDiabetes Mellitus Type II | Diabetes Mellitus Type IUnited States
-
HealthPartners InstituteInternational Diabetes Center at Park Nicollet; Park Nicollet Foundation; Melrose...TerminatedEating Disorder | Type I Diabetes Mellitus Without ComplicationUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Boston Children's HospitalCompletedType 1 Diabetes Mellitus | Glycemic ControlUnited States
-
DiaVacs, Inc.UnknownTreatment of Type I Diabetes Mellitus.United States
-
Sheba Medical CenterUnknownType I Diabetes Mellitus With Ulcer | Type II Diabetes Mellitus With UlcerIsrael
Clinical Trials on Artificial Pancreas Control Software
-
Legacy Health SystemJuvenile Diabetes Research FoundationCompleted
-
Docbot, Inc.RecruitingColorectal Adenoma | Colorectal Adenocarcinoma | Colorectal Polyp | Colorectal SSAUnited States
-
Kochi UniversityUniversity of Tokushima; Oita UniversityUnknownCardiovascular Diseases | Pancreatic DiseaseJapan
-
The University of Texas Health Science Center,...Recruiting
-
University of VirginiaJuvenile Diabetes Research Foundation; University of California, Santa BarbaraCompleted
-
Yale UniversityHarvard UniversityCompletedType1 DiabetesUnited States
-
University of VirginiaUniversity Hospital, Montpellier; University of Padova; University of California...CompletedType 1 Diabetes MellitusItaly
-
Peking University Third HospitalNot yet recruiting
-
University of VirginiaUniversity Hospital, Montpellier; University of Padova; University of California...CompletedType 1 Diabetes MellitusFrance
-
Sansum Diabetes Research InstituteHarvard UniversityCompletedType 1 Diabetes MellitusUnited States